Calidi Biotherapeutics, Inc. Increase (Decrease) in Accrued Liabilities
Calidi Biotherapeutics, Inc. (CLDI) reported Increase (Decrease) in Accrued Liabilities of $2.57 million for the 6-month period ending 2023-06-30, per its 10-Q filed 2023-08-21.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2023-08-21
- Calidi Biotherapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2023-06-30 was $985.45K.
- Calidi Biotherapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2023-03-31 was $1.58M.
- Calidi Biotherapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2022-12-31 was $2.44M, a 690.68% increase year-over-year.
- Calidi Biotherapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2022-09-30 was $465.45K.
- Calidi Biotherapeutics, Inc. increase (decrease) in accrued liabilities for fiscal 2022 was $2.87M.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2023-06-30 | $985.45K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-21 | $2.57M 10-Q · filed 2023-08-21 | $5.01M derived: sum of 3 quarters · filed 2023-08-21 | $5.48M derived: sum of 4 quarters · filed 2023-08-21 |
| 2023-03-31 | $1.58M 10-Q · filed 2023-05-15 | $4.03M derived: sum of 2 quarters · filed 2023-05-15 | $4.49M derived: sum of 3 quarters · filed 2023-05-15 | $4.48M derived: sum of 4 quarters · filed 2023-08-21 |
| 2022-12-31 | $2.44M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $2.91M derived: sum of 2 quarters · filed 2023-03-31 | $2.89M derived: sum of 3 quarters · filed 2023-08-21 | $2.87M 10-K · filed 2023-03-31 |
| 2022-09-30 | $465.45K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $451.74K derived: sum of 2 quarters · filed 2023-08-21 | $429.42K 10-Q · filed 2022-11-14 | $738.40K derived: sum of 4 quarters · filed 2023-08-21 |
| 2022-06-30 | -$13.71K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-21 | -$36.03K 10-Q · filed 2023-08-21 | $272.95K derived: sum of 3 quarters · filed 2023-08-21 | $258.32K derived: sum of 4 quarters · filed 2023-08-21 |
| 2022-03-31 | -$22.32K 10-Q · filed 2023-05-15 | $286.66K derived: sum of 2 quarters · filed 2023-05-15 | $272.02K derived: sum of 3 quarters · filed 2023-05-15 | $324.82K derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $308.98K derived: 10-K 9 month − 10-Q 6 month · filed 2023-03-31 | $294.35K derived: sum of 2 quarters · filed 2023-03-31 | $347.15K 10-K · filed 2023-03-31 | |
| 2021-09-30 | -$14.64K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-11-12 | $38.16K 10-Q · filed 2021-11-12 | ||
| 2021-06-30 | $52.80K 10-Q · filed 2022-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |